Skip to main content
Erschienen in: International Journal of Colorectal Disease 6/2013

01.06.2013 | Original Article

Clinicopathological features of ulcerative colitis-associated colorectal cancer pointing to efficiency of surveillance colonoscopy in a large retrospective Japanese cohort

verfasst von: Hiroki Matsuoka, Hiroki Ikeuchi, Motoi Uchino, Toshihiro Bando, Yoshio Takesue, Takayuki Nishigami, Naohiro Tomita

Erschienen in: International Journal of Colorectal Disease | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Cancer surveillance has been conducted in patients with ulcerative colitis (UC), and the number of operative cases of ulcerative colitis-associated colorectal cancer (UC-CRC) has been increasing. The aim of this study was to clarify the clinicopathological features and prognoses of UC-CRC patients and the relationship between surveillance colonoscopy and UC-CRC.

Methods

The clinical records of 1,274 UC patients who required surgery between 1984 and 2010 at a single institution were reviewed retrospectively. Of these, 83 patients had CRC (107 sections). All cases were extracted from the database, along with their clinicopathological data.

Results

The 5-year survival rate of the UC-CRC group was 89 %. The 5-year survival rate was 100 % in stages 0 and II, 96 % in stage I, 56 % in stage III, and 0 % in stage IV. Surveillance colonoscopy was performed for 40 of the 83 patients. Of 40 patients, 30 with UC who underwent surveillance colonoscopies and 22 of 43 patients without surveillance colonoscopies were in stages 0 to I (P = 0.04).

Conclusion

The number of UC-CRC patients who are diagnosed by surveillance colonoscopy is increasing, and many of them are detected in the very early stages (stages 0 or I). Thus, the survival rate of UC-CRC is better than before. Surveillance colonoscopy proofs efficient as CRC are detected in earlier stages.
Literatur
1.
Zurück zum Zitat Ekbom A, Heimick C, Zack M, Adami HO (1990) Ulcerative colitis and colorectal cancer. A population based study. N Engl J Med 323:1228–1233PubMedCrossRef Ekbom A, Heimick C, Zack M, Adami HO (1990) Ulcerative colitis and colorectal cancer. A population based study. N Engl J Med 323:1228–1233PubMedCrossRef
2.
Zurück zum Zitat Van Staa TP, Card T, Logan RF, Logan RF, Leufkens HG (2005) 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut 54:1573–1578PubMedCrossRef Van Staa TP, Card T, Logan RF, Logan RF, Leufkens HG (2005) 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut 54:1573–1578PubMedCrossRef
3.
Zurück zum Zitat Baumgart DC, Sandborn WJ (2007) Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 369:1641–1657PubMedCrossRef Baumgart DC, Sandborn WJ (2007) Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 369:1641–1657PubMedCrossRef
4.
Zurück zum Zitat Byers T, Levin B, Rothenberger DA, Dodd GD, Smith RA (1997) American cancer society guidelines for screening and surveillance for early detection of colorectal polyps and cancer: update 1997. American cancer society detection and treatment advisory group on colorectal cancer. CA Cancer J Clin 47:154–160PubMedCrossRef Byers T, Levin B, Rothenberger DA, Dodd GD, Smith RA (1997) American cancer society guidelines for screening and surveillance for early detection of colorectal polyps and cancer: update 1997. American cancer society detection and treatment advisory group on colorectal cancer. CA Cancer J Clin 47:154–160PubMedCrossRef
5.
Zurück zum Zitat Watanabe T, Konishi T, Kishimoto J et al (2011) Ulcerative colitis-associated colorectal cancer shows a poorer survival than sporadic colorectal cancer: a nationwide Japanese study. Inflamm Bowel Dis 17:802–808PubMedCrossRef Watanabe T, Konishi T, Kishimoto J et al (2011) Ulcerative colitis-associated colorectal cancer shows a poorer survival than sporadic colorectal cancer: a nationwide Japanese study. Inflamm Bowel Dis 17:802–808PubMedCrossRef
6.
Zurück zum Zitat Truelove SC, Witts LJ (1995) Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J 24947:1041–1048 Truelove SC, Witts LJ (1995) Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J 24947:1041–1048
7.
Zurück zum Zitat Heimann TM, Greenstein AJ, Bolnick K, Yoelson S, Aufses AH (1985) Colorectal cancer in familial polyposis and ulcerative colitis. Dis Colon Rectum 28:658–661PubMedCrossRef Heimann TM, Greenstein AJ, Bolnick K, Yoelson S, Aufses AH (1985) Colorectal cancer in familial polyposis and ulcerative colitis. Dis Colon Rectum 28:658–661PubMedCrossRef
8.
Zurück zum Zitat Eaden JA, Abrams KR, Mayberry JF (2001) The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48:526–535PubMedCrossRef Eaden JA, Abrams KR, Mayberry JF (2001) The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48:526–535PubMedCrossRef
9.
Zurück zum Zitat Pinczowski D, Ekbom A, Baron J, Yuen J, Adami HO (1994) Risk factors for colorectal cancer in patients with ulcerative colitis: a case–control study. Gastroenterology 107:117–120PubMed Pinczowski D, Ekbom A, Baron J, Yuen J, Adami HO (1994) Risk factors for colorectal cancer in patients with ulcerative colitis: a case–control study. Gastroenterology 107:117–120PubMed
10.
Zurück zum Zitat Rutter M, Saunders B, Wilkinson K et al (2004) Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 126:451–459PubMedCrossRef Rutter M, Saunders B, Wilkinson K et al (2004) Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 126:451–459PubMedCrossRef
11.
Zurück zum Zitat Rubin DT, Cruz-correa MR, Gasche C et al (2008) Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update. Inflamm Bowel Dis 14:265–274PubMedCrossRef Rubin DT, Cruz-correa MR, Gasche C et al (2008) Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update. Inflamm Bowel Dis 14:265–274PubMedCrossRef
12.
Zurück zum Zitat Velayos FS, Terdiman JP, Walsh JM (2005) Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 100:1345–1353PubMedCrossRef Velayos FS, Terdiman JP, Walsh JM (2005) Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 100:1345–1353PubMedCrossRef
13.
Zurück zum Zitat Chan EP, Lichtenstein GR (2006) Chemoprevention risk reduction with medical therapy of inflammatory bowel disease. Gastroenterol Clin North Am 35:675–712PubMedCrossRef Chan EP, Lichtenstein GR (2006) Chemoprevention risk reduction with medical therapy of inflammatory bowel disease. Gastroenterol Clin North Am 35:675–712PubMedCrossRef
14.
Zurück zum Zitat Bernstein CN, Nugent Z, Blanchard JF (2011) 5-Aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study. Am J Gastroenterol 106:731–736PubMedCrossRef Bernstein CN, Nugent Z, Blanchard JF (2011) 5-Aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study. Am J Gastroenterol 106:731–736PubMedCrossRef
15.
Zurück zum Zitat Baars JE, Looman CW, Steyerberg EW et al (2011) The risk of inflammatory bowel disease-related colorectal carcinoma is limited result from a nationwide nested case–control study. Am J Gastroenterol 106:319–328PubMedCrossRef Baars JE, Looman CW, Steyerberg EW et al (2011) The risk of inflammatory bowel disease-related colorectal carcinoma is limited result from a nationwide nested case–control study. Am J Gastroenterol 106:319–328PubMedCrossRef
16.
Zurück zum Zitat Actis GC, Pellicano R, David E, Sapino A (2010) Azathioprine, mucosal healing in ulcerative colitis, and the chemoprevention of colitic cancer: a clinical-practice-based forecast. Inflamm Allergy Drug Targets 9:6–9PubMedCrossRef Actis GC, Pellicano R, David E, Sapino A (2010) Azathioprine, mucosal healing in ulcerative colitis, and the chemoprevention of colitic cancer: a clinical-practice-based forecast. Inflamm Allergy Drug Targets 9:6–9PubMedCrossRef
17.
Zurück zum Zitat Rubin DT (2006) The changing face of colorectal cancer in inflammatory bowel disease: progress at least! Gastroenterology 130:1350–1352PubMedCrossRef Rubin DT (2006) The changing face of colorectal cancer in inflammatory bowel disease: progress at least! Gastroenterology 130:1350–1352PubMedCrossRef
18.
Zurück zum Zitat Chambers WM, Warren BF, Jewell DP, Mortensen NJ (2005) Cancer surveillance in ulcerative colitis. Br J Surg 92:928–936PubMedCrossRef Chambers WM, Warren BF, Jewell DP, Mortensen NJ (2005) Cancer surveillance in ulcerative colitis. Br J Surg 92:928–936PubMedCrossRef
19.
Zurück zum Zitat Ohman U (1982) Colorectal carcinoma in patients with ulcerative colitis. Am J Surg 144:344–349PubMedCrossRef Ohman U (1982) Colorectal carcinoma in patients with ulcerative colitis. Am J Surg 144:344–349PubMedCrossRef
20.
Zurück zum Zitat Jensen AB, Larsen M, Gislum M et al (2006) Survival after colorectal cancer in patients with ulcerative colitis: a nationwide population-based Danish study. Am J Gastroenterol 101:1283–1287PubMedCrossRef Jensen AB, Larsen M, Gislum M et al (2006) Survival after colorectal cancer in patients with ulcerative colitis: a nationwide population-based Danish study. Am J Gastroenterol 101:1283–1287PubMedCrossRef
21.
Zurück zum Zitat Lavery IC, Chiulli RA, Jagelman DG, Fazio VW, Weakley FL (1982) Survival with carcinoma arising in mucosal ulcerative colitis. Ann Surg 195:508–512PubMedCrossRef Lavery IC, Chiulli RA, Jagelman DG, Fazio VW, Weakley FL (1982) Survival with carcinoma arising in mucosal ulcerative colitis. Ann Surg 195:508–512PubMedCrossRef
22.
Zurück zum Zitat Sugita A, Greenstein AJ, Ribeiro MB et al (1993) Survival with colorectal cancer in ulcerative colitis. A study of 102 cases. Ann Surg 218:189–195PubMedCrossRef Sugita A, Greenstein AJ, Ribeiro MB et al (1993) Survival with colorectal cancer in ulcerative colitis. A study of 102 cases. Ann Surg 218:189–195PubMedCrossRef
Metadaten
Titel
Clinicopathological features of ulcerative colitis-associated colorectal cancer pointing to efficiency of surveillance colonoscopy in a large retrospective Japanese cohort
verfasst von
Hiroki Matsuoka
Hiroki Ikeuchi
Motoi Uchino
Toshihiro Bando
Yoshio Takesue
Takayuki Nishigami
Naohiro Tomita
Publikationsdatum
01.06.2013
Verlag
Springer-Verlag
Erschienen in
International Journal of Colorectal Disease / Ausgabe 6/2013
Print ISSN: 0179-1958
Elektronische ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-012-1592-6

Weitere Artikel der Ausgabe 6/2013

International Journal of Colorectal Disease 6/2013 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.